FDA Approves MONOVISC, a new single injection treatment for treatment of pain due to osteoarthritis of the knee

26-02-2014 Business Wire HealthComments (0)

Anika TherapeuticsUSA

Anika Therapeutics (NASDAQ:ANIK) today announced it has received marketing approval for MONOVISC from the US Food and Drug Administration (FDA). MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering from osteoarthritis (OA) of the knee. MONOVISC is the first FDA approved single injection product with HA from a non-animal source. It is comprised of a st

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top